<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p78" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_78{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_78{left:341px;bottom:30px;}
#t3_78{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_78{left:377px;bottom:30px;}
#t5_78{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_78{left:540px;bottom:30px;}
#t7_78{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_78{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_78{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_78{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_78{left:285px;bottom:827px;letter-spacing:-0.25px;}
#tc_78{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_78{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_78{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_78{left:1118px;bottom:47px;letter-spacing:0.34px;}
#tg_78{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_78{left:36px;bottom:284px;}
#ti_78{left:46px;bottom:278px;letter-spacing:0.13px;}
#tj_78{left:36px;bottom:267px;}
#tk_78{left:46px;bottom:261px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tl_78{left:377px;bottom:261px;letter-spacing:0.12px;}
#tm_78{left:407px;bottom:261px;letter-spacing:0.13px;}
#tn_78{left:481px;bottom:261px;}
#to_78{left:36px;bottom:250px;}
#tp_78{left:46px;bottom:244px;letter-spacing:0.11px;word-spacing:0.02px;}
#tq_78{left:45px;bottom:227px;letter-spacing:0.12px;}
#tr_78{left:36px;bottom:217px;}
#ts_78{left:46px;bottom:211px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tt_78{left:556px;bottom:211px;}
#tu_78{left:36px;bottom:200px;}
#tv_78{left:46px;bottom:194px;letter-spacing:0.12px;}
#tw_78{left:45px;bottom:177px;letter-spacing:0.12px;word-spacing:0.01px;}
#tx_78{left:45px;bottom:160px;letter-spacing:0.14px;}
#ty_78{left:36px;bottom:149px;}
#tz_78{left:46px;bottom:143px;letter-spacing:0.1px;word-spacing:-0.08px;}
#t10_78{left:45px;bottom:127px;letter-spacing:0.13px;}
#t11_78{left:45px;bottom:110px;letter-spacing:0.14px;}
#t12_78{left:432px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t13_78{left:759px;bottom:786px;letter-spacing:-0.12px;}
#t14_78{left:36px;bottom:748px;letter-spacing:-0.24px;}
#t15_78{left:36px;bottom:729px;letter-spacing:-0.1px;}
#t16_78{left:351px;bottom:737px;letter-spacing:-0.12px;}
#t17_78{left:36px;bottom:711px;}
#t18_78{left:47px;bottom:711px;letter-spacing:-0.09px;}
#t19_78{left:36px;bottom:693px;letter-spacing:-0.1px;}
#t1a_78{left:41px;bottom:674px;}
#t1b_78{left:58px;bottom:674px;letter-spacing:-0.09px;word-spacing:-0.07px;}
#t1c_78{left:616px;bottom:674px;letter-spacing:-0.12px;}
#t1d_78{left:668px;bottom:674px;}
#t1e_78{left:63px;bottom:656px;}
#t1f_78{left:76px;bottom:656px;letter-spacing:-0.09px;}
#t1g_78{left:77px;bottom:638px;letter-spacing:-0.09px;}
#t1h_78{left:41px;bottom:619px;}
#t1i_78{left:58px;bottom:619px;letter-spacing:-0.09px;}
#t1j_78{left:63px;bottom:601px;}
#t1k_78{left:76px;bottom:601px;letter-spacing:-0.09px;}
#t1l_78{left:547px;bottom:608px;}
#t1m_78{left:36px;bottom:546px;letter-spacing:-0.09px;}
#t1n_78{left:36px;bottom:528px;letter-spacing:-0.09px;}
#t1o_78{left:36px;bottom:509px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t1p_78{left:669px;bottom:236px;}
#t1q_78{left:680px;bottom:231px;letter-spacing:0.08px;word-spacing:0.01px;}
#t1r_78{left:678px;bottom:214px;letter-spacing:0.11px;word-spacing:-0.08px;}
#t1s_78{left:678px;bottom:197px;letter-spacing:0.12px;}
#t1t_78{left:678px;bottom:180px;letter-spacing:0.13px;word-spacing:0.01px;}
#t1u_78{left:669px;bottom:169px;letter-spacing:0.08px;}
#t1v_78{left:686px;bottom:163px;letter-spacing:0.09px;word-spacing:0.02px;}
#t1w_78{left:678px;bottom:146px;letter-spacing:0.12px;}
#t1x_78{left:678px;bottom:130px;letter-spacing:0.13px;}
#t1y_78{left:678px;bottom:113px;letter-spacing:0.1px;word-spacing:0.02px;}
#t1z_78{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_78{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_78{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_78{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_78{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_78{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_78{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_78{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_78{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_78{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s9_78{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_78{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_78{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sc_78{font-size:17px;font-family:Webdings_k6;color:#000;}
.sd_78{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.se_78{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sf_78{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts78" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg78Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg78" style="-webkit-user-select: none;"><object width="1210" height="935" data="78/78.svg" type="image/svg+xml" id="pdf78" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_78" class="t s0_78">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_78" class="t s1_78">® </span>
<span id="t3_78" class="t s0_78">(NCCN </span>
<span id="t4_78" class="t s1_78">® </span>
<span id="t5_78" class="t s0_78">), All rights reserved. NCCN Guidelines </span>
<span id="t6_78" class="t s1_78">® </span>
<span id="t7_78" class="t s0_78">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_78" class="t s2_78">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_78" class="t s2_78">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_78" class="t s3_78">NCCN Guidelines Version 4.2024 </span>
<span id="tb_78" class="t s3_78">Occult Primary </span>
<span id="tc_78" class="t s4_78">NCCN Guidelines Index </span>
<span id="td_78" class="t s4_78">Table of Contents </span>
<span id="te_78" class="t s4_78">Discussion </span>
<span id="tf_78" class="t s5_78">OCC-A </span>
<span id="tg_78" class="t s5_78">2 OF 2 </span>
<span id="th_78" class="t s6_78">1 </span>
<span id="ti_78" class="t s7_78">For squamous cell carcinoma, adenocarcinoma, and poorly differentiated carcinoma. </span>
<span id="tj_78" class="t s6_78">2 </span>
<span id="tk_78" class="t s8_78">See Principles of Radiation Techniques (RAD-A) </span><span id="tl_78" class="t s7_78">and </span><span id="tm_78" class="t s8_78">Discussion</span><span id="tn_78" class="t s7_78">. </span>
<span id="to_78" class="t s6_78">4 </span>
<span id="tp_78" class="t s7_78">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose </span>
<span id="tq_78" class="t s7_78">painting technique (dependent on dose per fraction). </span>
<span id="tr_78" class="t s6_78">5 </span>
<span id="ts_78" class="t s8_78">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tt_78" class="t s7_78">. </span>
<span id="tu_78" class="t s6_78">7 </span>
<span id="tv_78" class="t s9_78">Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without </span>
<span id="tw_78" class="t s7_78">concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med </span>
<span id="tx_78" class="t s7_78">2004;350:1945-1952. </span>
<span id="ty_78" class="t s6_78">8 </span>
<span id="tz_78" class="t s7_78">Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and </span>
<span id="t10_78" class="t s7_78">chemotherapy for high-risk squamous-cell carcinoma of the head and neck. </span>
<span id="t11_78" class="t s7_78">N Engl J Med 2004;350:1937-1944. </span>
<span id="t12_78" class="t s5_78">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t13_78" class="t sa_78">1,2 </span>
<span id="t14_78" class="t s5_78">POSTOPERATIVE: </span>
<span id="t15_78" class="t s5_78">RT or Concurrent Systemic Therapy/RT </span>
<span id="t16_78" class="t sa_78">5,7-10 </span>
<span id="t17_78" class="t s5_78">• </span><span id="t18_78" class="t sb_78">Preferred interval between resection and postoperative RT is ≤6 weeks </span>
<span id="t19_78" class="t s5_78">• PTV </span>
<span id="t1a_78" class="t sc_78"></span><span id="t1b_78" class="t s5_78">High risk: Adverse pathologic features such as extranodal extension (</span><span id="t1c_78" class="t sd_78">OCC-4</span><span id="t1d_78" class="t s5_78">) </span>
<span id="t1e_78" class="t se_78">◊ </span><span id="t1f_78" class="t sb_78" data-mappings='[[81,"fi"]]'>Mucosal dose: 50–66 Gy (2.0 Gy/fraction) to putative mucosal sites, depending on ﬁeld size. Consider higher dose to 60–66 Gy to </span>
<span id="t1g_78" class="t s5_78">particularly suspicious areas </span>
<span id="t1h_78" class="t sc_78"></span><span id="t1i_78" class="t s5_78">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1j_78" class="t se_78">◊ </span><span id="t1k_78" class="t s5_78">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1l_78" class="t sa_78">4 </span>
<span id="t1m_78" class="t s5_78">Either IMRT (preferred) or 3D-CRT is recommended when targeting the pharyngeal axis to minimize the dose to critical structures. Use of </span>
<span id="t1n_78" class="t s5_78">proton therapy is an area of active investigation. Proton therapy may be considered when normal tissue constraints cannot be met by photon- </span>
<span id="t1o_78" class="t s5_78">based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </span>
<span id="t1p_78" class="t s6_78">9 </span>
<span id="t1q_78" class="t s7_78">Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally </span>
<span id="t1r_78" class="t s7_78">advanced head and neck cancers: A comparative analysis of concurrent </span>
<span id="t1s_78" class="t s7_78">postoperative radiation plus chemotherapy trials of the EORTC (#22931) </span>
<span id="t1t_78" class="t s7_78">and RTOG (#9501). Head Neck 2005;27:843-850. </span>
<span id="t1u_78" class="t s6_78">10 </span>
<span id="t1v_78" class="t s7_78">Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG </span>
<span id="t1w_78" class="t s7_78">9501/intergroup phase III trial: postoperative concurrent radiation therapy </span>
<span id="t1x_78" class="t s7_78">and chemotherapy in high-risk squamous cell carcinoma of the head and </span>
<span id="t1y_78" class="t s7_78">neck. Int J Radiat Oncol Biol Phys 2012;84:1198-1205. </span>
<span id="t1z_78" class="t sf_78">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
